The article by Wibmer and colleagues from the Memorial Sloan Kettering Cancer Center in New York, New York, provides a state-of-the-art review of the molecular imaging of prostate cancer, currently the most common noncutaneous malignancy diagnosed in the United States. In their article, the authors discuss the use of a spectrum of radiolabeled analogs of metabolic substrates that can be used in the detection and staging of prostate cancer. Particular focus is placed on the use of choline, 11C-acetate, FACBC (as an analog of L-leucine), 18F-fluorodeoxyglucose, and prostate-specific membrane antigen. While the relative utility of these methods continues to evolve, there is no question that imaging strategies employed in the evaluation of prostate cancer patients will incorporate molecular imaging tools in the near future. Peter Choyke, MD, from the Molecular Imaging Program, National Cancer Institute Bethesda, Maryland, provides an expert commentary on the potential role of molecular imaging agents in prostate cancer and the challenges of receiving approval of and reimbursement for use of these probes.
Read Full Text: [ Ссылка ]
Read Invited Commentary: [ Ссылка ]
Also please find a related article in the January-February 2016 issue of RadioGraphicson the use of 11C-choline PET/CT in prostate cancer and nonprostatic neoplastic processes by Welle et al. [ Ссылка ]
c) 2016 The Radiological Society of North America
[ Ссылка ]
